IDH1 and glioblastoma: Though this study was performed prior to revision of GBM diagnostic criteria to exclude patients with mutations in IDH, a subset analysis showed that survival among patients without the IDH R132H mutation was equivalent to the survival for all patients (IDH-mutant and wild-type) who received the treatment (12.5 months in both groups).